Volume 21, Number 1 (April 2014)                   J Birjand Univ Med Sci. 2014, 21(1): 86-95 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shahraki A, Zakeri Z, Hosseinian M, Hajnegad S. interleukin-33 and interleukin-18 serum levels in patients with rheumatoid arthritis and osteoporosis. J Birjand Univ Med Sci.. 2014; 21 (1) :86-95
URL: http://journal.bums.ac.ir/article-1-1419-en.html

1- Assistant professor, Department of Biology, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran , ashahraki@science.usb.ac.ir
2- Associate professor, Department of internal medicine, Faculty of Science, University of Sistan and Baluchestan, Zahedan, Iran.
3- MSc of Biochemistry, Department of Biology, university of Sistan and Baluchestan, Zahedan, Iran.
Abstract:   (6355 Views)
Background and Aim: Limited studies have been focused on the role of IL-33 and IL-18 in Rheumatoid arthritis (RA).This study was done to measure the levels of IL-18 and IL-33 in the serum of patients with RA, before treatment, three month after treatment and compare to patients with osteoporosis as well as healthy controls. Materials and Methods: Sera were obtained from 20 patients with RA before treatment, 15 patients with osteoporosis and 30 healthy controls that have been matched to patients group. IL-33 and IL-18 levels were measured using ELISA assay. Results: Serum levels of IL-33 were significantly higher in patients with RA before treatment 5.47± 0.142 (pg/ml) versus three months after treatment 4.34±0.072, P=0.001, and control subjects 4.53±.076 (pg/ml), P=0.000. There were significant differences between IL-33 serum levels in patients with RA before treatment compare to osteoporosis subjects before treatment (5.47± 0.142 versus 3.65±0.08, P=0.000). The serum IL-18 levels of the RA patients before treatment 482.12±67.38 (pg/ml) were significantly higher than the IL-18 level three months after treatment 302.67±55.33 (pg/ml) P=0.004, the control group 216.19±47.56 (pg/ml) P= 0.004 and patients with OP 316.79±53.72, p= 0.001. Conclusion: Our results showed that IL-33 and IL-18 are highly active in RA and these cytokines might be closely involved in the pathologic mechanisms of the disease.
Full-Text [PDF 209 kb]   (1028 Downloads)    
Subject: Rheumatology
Received: 2013/05/28 | Accepted: 2014/04/13 | Published: 2014/06/10

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author


© 2015 All Rights Reserved | Journal of Birjand University of Medical Sciences

Designed & Developed by : Yektaweb